MONOPAR THERAPEUTICS INC.

Analyst Reco. Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-06 pm EDT			5-day change	1st Jan Change
0.9297 ^USD	+15.49%		+51.79%	+173.28%

May. 24	Monopar Therapeutics Names Karthik Radhakrishnan as CFO	MT
May. 24	Monopar Therapeutics Inc. Announces CFO Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JonesTrading Upgrades Monopar Therapeutics to Buy From Hold, Price Target is $2	Apr. 11	MT
JonesTrading Downgrades Monopar Therapeutics to Hold From Buy	23-08-10	MT
HC Wainwright Adjusts Monopar Therapeutics' Price Target to $2 From $6, Keeps Buy Rating	23-05-15	MT
Maxim Group Downgrades Monopar Therapeutics to Hold From Buy	23-03-29	MT
Roth MKM Adjusts Price Target on Monopar Therapeutics to $3 From $18, Maintains Buy Rating	23-03-28	MT
EF Hutton Adjusts Price Target on Monopar Therapeutics to $17 From $24, Maintains Buy Rating	23-03-28	MT
Roth Capital Reinstates Monopar Therapeutics at Buy With $18 Price Target	22-12-09	MT
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High	22-10-05	MT
HC Wainwright Adjusts Monopar Therapeutics' Price Target to $6 From $9, Maintains Buy Rating	22-08-16	MT
HC Wainwright Starts Monopar Therapeutics at Buy With $9 Price Target	21-11-01	MT
MONOPAR THERAPEUTICS : Roth Capital Starts Monopar Therapeutics at Buy With $49 Price Target	21-01-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer